Verquvo™ (vericiguat) – New drug approval
January 20, 2021 - Merck announced the FDA approval of Verquvo (vericiguat), to reduce the risk of cardiovascular (CV) death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient intravenous diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.
Top